We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

MorphoSys AG has announced the signing of a protein engineering agreement with a large bio-pharmaceutical company. The non-exclusive license agreement covers the delivery of multiple Slonomics®-based DNA libraries.

The libraries will encode a broad range of protein classes, excluding antibodies, and will be used by its partner for drug discovery.

MorphoSys will receive committed annual funding for the delivery of libraries over the three-year lifetime of the agreement and stands to receive milestone and royalty payments on each product emerging from the collaboration.

"This fourth alliance around the Slonomics technology further illustrates the value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

Dr. Moroney continued, "Slonomics is a powerful method for making libraries of all types, and this agreement exemplifies the commercial opportunity it creates for us beyond the antibody field."

The Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed.

The technology provides a new and flexible approach to generating optimized proteins. MorphoSys acquired Slonomics through Sloning BioTechnology in October 2010.